HALLE (SAALE) / MUNICH, GERMANY, 14 April 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) announced today that the publication of the Full Year 2020 […]
HALLE (SAALE) / MUNICH, GERMANY, 1 April 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) announced today that it will host a virtual event […]
All proposed resolutions approved with large majority HALLE (SAALE) / MUNICH, GERMANY, 12 March 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) announced today […]
HALLE (SAALE) / MUNICH, GERMANY, 29 January 2021 – the Board of Directors (Board) of Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) announced today that […]
HALLE (SAALE) / MUNICH, Germany, 06 January 2021 – in connection with the conversion into an N.V., a public company under the laws of the Netherlands (naamloze […]
HALLE (SAALE) / MUNICH, Germany, 16 December 2020 – as a consequence of the conversion into an N.V., a public company under the laws of the Netherlands […]
HALLE (SAALE) / MUNICH, GERMANY, 14 December 2020 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; ISIN DE0007921835) has been informed by Hauck & Aufhäuser Privatbankiers AG […]
HALLE (SAALE) / MUNICH, Germany, 30 November 2020 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) announced today that it has completed its conversion into an N.V., a […]
HALLE (SAALE) / MUNICH, Germany, 26 November 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN DE0007921835) announced today its third quarter business update for the period […]